YAŞA BAĞLI MAKULODİSTROFİYANIN EKSSUDATİV FORMASI ZAMANI ANTİANGİOGEN TERAPİYANIN GÖZÜN MORFOLOJİ VƏ FUNKSİONAL PARAMETLƏRİNƏ TƏSİRİ

Xülasə

SUMMARY

Aim – to learn the effciacy of VEGF blocator ranibizumab (Lucentis, Novartis Pharma) in patients with “wet” age-related maculodistrophy at the various stages of pathological process.

Material and methods
30 patients with “wet” form of age-related maculodistrophy were in the investigation. The man age was 65,1±1,3 years. The distribution according to the gender was as follows: 21 women and 9 men (30%). For estimation of the functional effciacy of the antiangiogenic therapy of the AMD “wet” form all patients were subjected to: evalution of the maximal corregated visual acuity, ocular tonometry with contactess tonometer (IOP =9-21 mm Hg was valued as normative); optical coherent tomography – OCT (Carl Zeiss Meditec, Spectral Cirrus HD OCT), microperimetry (Macular Integrity Assessment Italy).

Results - At the results of this treatment the increase of visual acuity with correction had been noted in all patients. In 1, 2 and 3 and 4 subgroups the retinal thickness after Lucentis had reliably decreased (p <0,05) in the average on 29,6 mkm, 23,3 mkm, 48 mkm and 59,6 mkm. Under the infuence of Lucentis preparation the indices of microperimetry had improved on 25dB, 21dB, 19dB accordingly in 1-st, 2-nd and 3-rd subgroups, but in patients with macular fbrosis (4-th subgroup) the absence of changes of luminous sensitivity of retina hadn’t been revealed.

Conclusion
Intravitreal introduction of antiangiogenic preparation Lucentis essentially improves the functional and morphological indices of retina in patients with the “wet” form of age-related maculodistrophy. Herewith, the most effective is the treatment at the earlier stages of diseases.